Buga, Liezel Joy .
HRN: 17-79-54 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
03/04/2023
CO-AMOXICLAV 625MG (TAB)
03/04/2023
03/11/2023
ORAL
625mg
BID
S/P NSVD With RMLE
Waiting Final Action
Indication: Empiric Type of Infection: Reproductive Tract Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes